Monday, 11 November 2013

Global Research On China Interventional Cardiovascular Device Industry Report, 2013 - 2015

Researchmoz presents this most up-to-date research on"China Interventional Cardiovascular Device Industry Report, 2013 - 2015".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients stimulated rapid growth in Chinese demand for interventional cardiac operation and coronary stent. 
China's PCI (percutaneous coronary intervention) surgeries increased from 25,000 cases in 2002 to about 531,000 cases in 2012; the number of coronary stent implantation rose from 40,000 units in 2002 to approximately 640,000 units in 2012. In 2007-2012 China's cardiovascular stent market size grew at an AAGR of 20.3%. 

In China, interventional cardiovascular devices are dominated by cardiovascular stent. Currently, the top three companies in China's coronary stent market are respectively MicroPort, Lepu Medical and JW Medical; while supporting auxiliary devices such as catheter and guide wire feature low localization rate, mainly dependent on imports. In 2012, Chinese enterprises accounted for 66.8% of Chinese interventional cardiovascular device market share, followed by foreign counterparts with 33.2%. 
Related Reports : 
MediPoint: Renal Denervation - EU Analysis and Market Forecasts
Numerous medical device news sources and industry executives have proclaimed renal denervation to be the top medical device breakthrough of the past two years, and for good reason. Hypertension is one of the most prevalent chronic conditions worldwide, with some studies estimating that 50% of the adult population globally will have the disease in the next 20 years. With limited effectiveness from pharmacotherapy, medical device therapy has the potential for significant adoption in the treatment of resistive hypertension and uncontrolled hypertension, once efficacy and cost-effectiveness are proven. Additionally, the degree of blood pressure reduction found in long-term clinical trials from such a well-tolerated procedure has generated notable optimism about the interventions application in other conditions where hyperactivity of the sympathetic nervous system plays a significant role, such as congestive heart failure.
LVADs are the mechanical devices which are implanted into the abdomen or chest and attached to a weakened heart to help it pump. LVADs are now sometimes used as an alternative to transplantation. LVAD is suitable for bridge-to-transplant market, which extends the patient’s life until a suitable donor is found, and for destination market, where patients suffer from heart failure but are not eligible for heart transplants, may be due to their age or some other illness that might get aggravated by heart transplantation. Due to increasing demand for both BTT and DT, LVAD market is increasing tremendously. Also, with the rapid technological advancements in this segment, LVADs are expected to become a viable treatment option for heart failure patients in the future.

Interventional cardiovascular device is a sunrise industry, there lies strong clinical demand for safer and more effective interventional products, and thus the world's major manufacturers have invested heavily in research and development of new products. Bioabsorbable everolimus-eluting stent (BVS) has become the focus of attention. 
Abbott in September 2012 launched the world's first A bioabsorbable everolimus-eluting coronary stent system (ABSORB), expected to bring a revolutionary change in coronary artery disease (CAD) treatment; MicroPort's third-generation completely biodegradable drug-eluting stent Firehawk has completed clinical trials in China; Lepu Medical's completely biodegradable drug-eluting stent is also in active research and development.
For Latest Reports Click Here

Table of Content

1. Overview of Interventional Cardiovascular Device Industry
1.1 Definition
1.2 Product Types and Applications
1.3 Industry Chain

2. Status Quo of China Interventional Cardiovascular Device Industry
2.1 Overview 
2.2 Market Demand 
2.3 Import and Export
2.4 Competition Pattern
2.5 Profit
2.6 Entry Barriers
2.6.1 Technology 
2.6.2 Talent 
2.6.3 Patent 
2.6.4 Policy 
2.6.5 Market Access 

3. Development Environment for China Interventional Cardiovascular Device Industry
3.1 Policy Environment
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Sectors
3.2.1 Upstream
3.2.2 Downstream


No comments:

Post a Comment